DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Public ClinicalTrials.gov record NCT04567420. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Study identification
- NCT ID
- NCT04567420
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 8, 2021
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2028
- Last update posted
- Jul 7, 2026
2021 – 2028
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Intermountain | Golden | Colorado | 80401 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Louisiana State University Health Sciences Center- New Orleans | New Orleans | Louisiana | 70112 | — |
| Cancer Partners of Nebraska | Lincoln | Nebraska | 68516 | — |
| New Mexico Cancer Care Alliance | Albuquerque | New Mexico | 87131 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Stony Brook University Cancer Center | Stony Brook | New York | 11794 | — |
| The Ohio State University Wexner Medical Center James Cancer Hospital | Columbus | Ohio | 43210 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| PRiSMs Group | Laredo | Texas | 78041 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23229 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| University of Wisconsin Clinical Science Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04567420, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04567420 live on ClinicalTrials.gov.